BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 24479685)

  • 1. Interferon-γ induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages.
    Kuss M; Adamopoulou E; Kahle PJ
    J Neurochem; 2014 Jun; 129(6):980-7. PubMed ID: 24479685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
    Gillardon F; Schmid R; Draheim H
    Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2: dropping (kinase) inhibitions and seeking an (immune) response.
    Mamais A; Cookson MR
    J Neurochem; 2014 Jun; 129(6):895-7. PubMed ID: 24661004
    [No Abstract]   [Full Text] [Related]  

  • 4. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.
    Deng X; Elkins JM; Zhang J; Yang Q; Erazo T; Gomez N; Choi HG; Wang J; Dzamko N; Lee JD; Sim T; Kim N; Alessi DR; Lizcano JM; Knapp S; Gray NS
    Eur J Med Chem; 2013; 70():758-67. PubMed ID: 24239623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crohn's and Parkinson's Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in Human CD14
    Ikezu T; Koro L; Wolozin B; Farraye FA; Strongosky AJ; Wszolek ZK
    J Neuroimmune Pharmacol; 2020 Dec; 15(4):794-800. PubMed ID: 32180132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1.
    Luerman GC; Nguyen C; Samaroo H; Loos P; Xi H; Hurtado-Lorenzo A; Needle E; Stephen Noell G; Galatsis P; Dunlop J; Geoghegan KF; Hirst WD
    J Neurochem; 2014 Feb; 128(4):561-76. PubMed ID: 24117733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.
    Dzamko N; Inesta-Vaquera F; Zhang J; Xie C; Cai H; Arthur S; Tan L; Choi H; Gray N; Cohen P; Pedrioli P; Clark K; Alessi DR
    PLoS One; 2012; 7(6):e39132. PubMed ID: 22723946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to
    Weindel CG; Bell SL; Vail KJ; West KO; Patrick KL; Watson RO
    Elife; 2020 Feb; 9():. PubMed ID: 32057291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity.
    Heo HY; Park JM; Kim CH; Han BS; Kim KS; Seol W
    Exp Cell Res; 2010 Feb; 316(4):649-56. PubMed ID: 19769964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-γ signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells.
    Panagiotakopoulou V; Ivanyuk D; De Cicco S; Haq W; Arsić A; Yu C; Messelodi D; Oldrati M; Schöndorf DC; Perez MJ; Cassatella RP; Jakobi M; Schneiderhan-Marra N; Gasser T; Nikić-Spiegel I; Deleidi M
    Nat Commun; 2020 Oct; 11(1):5163. PubMed ID: 33057020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leucine-rich repeat kinase 2-sensitive Na+/Ca2+ exchanger activity in dendritic cells.
    Yan J; Almilaji A; Schmid E; Elvira B; Shimshek DR; van der Putten H; Wagner CA; Shumilina E; Lang F
    FASEB J; 2015 May; 29(5):1701-10. PubMed ID: 25609428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β.
    Kawakami F; Shimada N; Ohta E; Kagiya G; Kawashima R; Maekawa T; Maruyama H; Ichikawa T
    FEBS J; 2014 Jan; 281(1):3-13. PubMed ID: 24165324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.
    Daniëls V; Baekelandt V; Taymans JM
    Neurosignals; 2011; 19(1):1-15. PubMed ID: 21430363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.
    Yun H; Heo HY; Kim HH; DooKim N; Seol W
    Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 is involved in the IFN-gamma response and host response to pathogens.
    Gardet A; Benita Y; Li C; Sands BE; Ballester I; Stevens C; Korzenik JR; Rioux JD; Daly MJ; Xavier RJ; Podolsky DK
    J Immunol; 2010 Nov; 185(9):5577-85. PubMed ID: 20921534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells.
    Sarközi R; Miller B; Pollack V; Feifel E; Mayer G; Sorokin A; Schramek H
    J Cell Physiol; 2007 Apr; 211(1):88-100. PubMed ID: 17131384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein.
    Niu J; Yu M; Wang C; Xu Z
    J Neurochem; 2012 Aug; 122(3):650-8. PubMed ID: 22639965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Parkinson's disease-associated kinase LRRK2 regulates genes required for cell adhesion, polarization, and chemotaxis in activated murine macrophages.
    Levy DR; Udgata A; Tourlomousis P; Symmons MF; Hopkins LJ; Bryant CE; Gay NJ
    J Biol Chem; 2020 Jul; 295(31):10857-10867. PubMed ID: 32111741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.